Soluzione Tasse Spa (STG) Quote

The elections have nothing to do with Elite except being a positive force whichever candidate wins. Generic drugs are always welcome due to the low price compared to their original drug maker. The stock price got wallop during the bear raid and shorts are now in control and in the foreseeable future

Nice new A/C ...just made a trade IWM 221c in .55 out .68 not much about 23%

Should be 40 cents stock. Once FDA clearance obtained sky is the limit. Very small float

Oh, I know the answer to this....

ME!!!!

Looks like BLEG has become just another barcode chart!

ADDING .0027's...IMO under .004 is golden

Trying to take out the .0212s but GTSM probably has a big chunk there. Need consistent buying pressure otherwise the price will never move.

Yep!

MRNA is set to report third-quarter 2024 earnings on Nov. 7, before the opening bell. The Zacks Consensus Estimate for sales and earnings is pegged at $1.25 billion and a loss of $1.91 per share, respectively

I prefer to present the news rather than tell folks what to think....glass half empty??

Thanks to whoever sold me another 100k at .096.

GERN upgraded to $8 & stock sells off ?

Man !

https://hackernoon.com/why-cybercriminals-are-not-necessarily-embracing-ai
Now, wouldn't they hate Wave!

Linebacker™ adds unique value to IBO’s IP portfolio, potentially impacting arthritis, asthma, and more.

IBO’s patent approval for Linebacker™ in Canada brings its technology one step closer to benefiting patients.

I was not aware that there will be any type of reductions in the share structure coming..?? Was it said somewhere which I may have probably missed?

Surely would love to see that happening!!!

More promotional GARBAGE.

Spending? A history lesson. Obama walked into the worst economy since the Great Depression. After 8 years he handed the next administration the best economy ever handed off to an incoming president. $8 Trillion added to the nat.debt over 8 years. The next administration left office with the eco

Impact BioMedical’s Linebacker™ platform advances inflammatory disease management with this latest patent.

Global Reach: Immediate access to operations in 65+ countries and relationships with over 2,700 brands

This Canadian patent is a win for IBO, advancing its goal to offer alternative therapies for inflammatory diseases.

IBO’s patented Linebacker™ compounds present a promising alternative in the multi-billion-dollar inflammation treatment market.

For more information and direct inquiries about the ACGX PeopleVine business:
CONTACTS
+1 312-957-7737
Peoplevine Inc., 222 W Merchandise Mart Plaza #1212,
Chicago, IL 60654, United States
info@peoplevine.com

With this new patent, IBO’s innovative Linebacker™ platform is gaining significant traction in healthcare.

Wow

IBO’s Linebacker™ compounds hold great potential, offering relief to those with arthritis and similar conditions.